+1 800 783 4636

2015 IRI Scan Data Shows UC-ll® Joint Health Growth

Joint relief has long been a primary sector within the health supplement marketplace. It was one of the original benefits suggested and offered alongside daily vitamins, and the sector has grown ever since. In fact, joint relief claims the highest price per unit, driving a higher return on inventory investment. Recently, however, joint health has lost its competitive edge and fallen under the radar in the supplement industry.

In the year leading up to November 2015, glucosamine and chondroitin products which previously dominated the sector fell by 15%, while UC-ll® rose by 61%. It seems that the future of joint health may therefore lie in the growth of this new ingredient.

 

UC-ll® stands for undenatured type-II collagen, an ingredient that shows superior efficiency over glucosamine and chondroitin. The ingredient is powerful enough to require less and fewer dosages to produce an immense joint benefit. Where glucosamine pills are large and need to be taken 2-3 times each day, UC-ll® is small and only takes one dosage.

 

According to the founder and CEO of TABS analytics, “All the metrics are very positive. And so it looks like it’s not only going to be a fairly popular and productive presence in the market, but it looks like it has some significant growth potential over the next three to five years.”

 

The metrics mentioned above are factored by the two main drivers of sales: distribution and velocity. The key is to maintain velocity as distribution increases, and UC-ll® appears to be doing just that, according to the IRI scan data. In addition, there doesn’t seem to be a saturation point. This means that UC-ll® could drive sustained growth in the joint health sector for years to come.

 

Supplement manufacturers are encouraged to develop a UC-ll® product to gain a foothold in the growing market, partnering with InterHealth is the answer. UC-ll® is made in the United States with self-affirmed GRAS. No other ingredient provides a substantial benefit to mobility and flexibility in just 40 mg.

 

For more information on the clinical studies including manufacturing flow charts, marketing information, and how this ingredient can be incorporated into your product line, contact InterHealth at 1-800-783-4636.

Recent Posts

Sorry, the comment form is closed at this time.

Terms of Use

This is business-to-business information intended for food and supplement producers, and is not intended for the final consumer. This information is based on our own research and development work and is, to the best of our knowledge, reliable. However, Lonza does not assume any liability or risk involved in the use of this information, as conditions of use are beyond our control. Manufacturers should check local regulatory status of any claims according to the intended use of their products.

Privacy and Cookies Notice

 

Please note that Lonza has updated its Privacy Policy. By visiting our website or using services provided by Lonza, you are accepting the practices described in the Privacy Policy.

 

We also use cookies on our websites. Cookies allow us to give you the best browsing experience and help us to understand how you use our site. You can disable cookies but parts of our website may not work. Please read our updated Cookies Policy for information about which cookies we use and the information we collect. By continuing to use this website, you agree that we may store and access cookies on your device.

 

By clicking "I Agree", you confirm that you are above the age of 16, that you have read and understood the Privacy Policy and the Cookies Policy, and that you agree to the collection, use and processing of your Personal Information by Lonza in accordance with said policies.